Diagnosis, management and follow up of peripheral T-cell lymphomas: a consensus practice statement from the Australasian Lymphoma Alliance.

Autor: Hapgood G; Princess Alexandra Hospital, Brisbane, Queensland, Australia.; University of Queensland, Brisbane, Queensland, Australia., Latimer M; The Canberra Hospital, Canberra, Australian Capital Territory, Australia., Lee ST; Olivia Newton John Cancer Research Institute, Austin Health, Melbourne, Victoria, Australia.; University of Melbourne, Melbourne, Victoria, Australia., Kuss B; Flinders University, Adelaide, South Australia, Australia.; Flinders Medical Centre, Adelaide, South Australia, Australia., Lade S; Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia., Tobin JWD; Mater Health, Brisbane, Queensland, Australia.; Mater Research Institute, University of Queensland, Brisbane, Queensland, Australia., Purtill D; University of Western Australia, Perth, Western Australia, Australia.; Fiona Stanley Hospital, Perth, Western Australia, Australia., Campbell BA; University of Melbourne, Melbourne, Victoria, Australia.; Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia., Prince HM; University of Melbourne, Melbourne, Victoria, Australia.; Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia., Hawkes EA; Olivia Newton John Cancer Research Institute, Austin Health, Melbourne, Victoria, Australia.; University of Melbourne, Melbourne, Victoria, Australia.; Monash University, Melbourne, Victoria, Australia., Shortt J; Monash University, Melbourne, Victoria, Australia.; Monash Health, Melbourne, Victoria, Australia., Radeski D; University of Western Australia, Perth, Western Australia, Australia.; Sir Charles Gairdner Hospital, Perth, Western Australia, Australia.
Jazyk: angličtina
Zdroj: Internal medicine journal [Intern Med J] 2022 Oct; Vol. 52 (10), pp. 1806-1817.
DOI: 10.1111/imj.15595
Abstrakt: Peripheral T-cell lymphomas (PTCL) represent a heterogeneous disease group accounting for 10% of non-Hodgkin lymphomas. PTCL patients have typically poorer outcomes compared with aggressive B-cell lymphomas. However, such outcomes are heavily dependent on subtype. Although anthracycline-based regimens such as cyclophosphamide, doxorubicin, vincristine and prednisone remain the standard first-line treatment for most aggressive PTCL, there are important variations including incorporation of novel agents, use of radiotherapy and judicious consideration of stem cell transplantation. Relapsed or refractory disease represents a significant area of unmet need where chemotherapy intensification has limited efficacy and novel agents such as brentuximab vedotin and pralatrexate provide additional opportunities for attainment of remission and potential stem cell transplant. In the future, pre-therapy prognostic biomarkers including genomic characterisation, may aid in risk stratification and help guide initial patient management to improve survival. There is an urgent need to understand better the pathogenesis of PTCL to facilitate novel drug combinatorial approaches to improve survival. This position statement represents an evidence-based synthesis of the literature for application in Australian and New Zealand practice.
(© 2021 Royal Australasian College of Physicians.)
Databáze: MEDLINE
Externí odkaz: